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Abstract
Background: No cardiac biomarkers for detecting acute kidney injury (AKI) on admission in non-surgical intensive
care patients have been reported. The aim of the present study is to elucidate the role of cardiac biomarkers for
quickly identifying the presence of AKI on admission.
Methods: Data for 1183 patients who underwent the measurement of cardiac biomarkers, including the serum
heart-type fatty acid-binding protein (s-HFABP) level, in the emergency department were screened, and 494 non-
surgical intensive care patients were enrolled in this study. Based on the RIFLE classification, which was the ratio of
the serum creatinine value recorded on admission to the baseline creatinine value, the patients were assigned to a
no-AKI (n = 349) or AKI (Class R [n = 83], Class I [n = 36] and Class F [n = 26]) group on admission. We evaluated the
diagnostic value of the s-H-FABP level for detecting AKI and Class I/F. The mid-term prognosis, as all-cause death
within 180 days, was also evaluated.
Results: The s-H-FABP levels were significantly higher in the Class F (79.2 [29.9 to 200.3] ng/mL) than in the Class I
(41.5 [16.7 to 71.6] ng/mL), the Class R (21.1 [10.2 to 47.9] ng/mL), and no-AKI patients (8.8 [5.4 to 17.7] ng/mL). The
most predictive values for detecting AKI were Q2 (odds ratio [OR]: 3.743; 95 % confidence interval [CI]: 1.693–8.274),
Q3 (OR: 9.427; 95 % CI: 4.124–21.548), and Q4 (OR: 28.000; 95 % CI: 11.245–69.720), while those for Class I/F were Q3
(OR: 5.155; 95 % CI: 1.030–25.790) and Q4 (OR: 22.978; 95 % CI: 4.814–109.668). The s-HFABP level demonstrating an
optimal balance between sensitivity and specificity (70.3 and 72.8 %, respectively; area under the curve: 0.774; 95 %
CI: 0.728–0.819) was 15.7 ng/mL for AKI and 20.7 ng/mL for Class I/F (71.0 and 83.1 %, respectively; area under the
curve: 0.818; 95 % CI: 0.763–0.873). The prognosis was significantly poorer in the high serum HFABP with AKI group
than in the other groups.
Conclusions: The s-H-FABP level is an effective biomarker for detecting AKI in non-surgical intensive care patients.
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Background
The risk, injury, failure, loss, and end-stage (RIFLE)
criteria have been established as a standard method for
evaluating acute kidney injury (AKI) in intensive care
patients [1, 2]. In a previous study, we reported that
patients with AKI, particularly those with a Class I or F
status, exhibit worse in-hospital mortality rates and
long-term prognoses than no-AKI patients among
subjects with acute heart failure (AHF) [3, 4]. Further-
more, 33.2 % of AHF patients already have AKI upon
admission to the intensive care unit (ICU) [3], which is
associated with a poor in-hospital mortality rate and
long-term prognosis [5]. The presence of AKI on admis-
sion and a Class I or F status are important factors in
AHF patients; therefore, these findings are also import-
ant among overall non-surgical intensive care patients.
In clinical situations, the detection of AKI on admission,
especially a Class F status, is an immediate and essential
problem in non-surgical intensive care patients. The
timely diagnosis of AKI might propitiate early adjust-
ment of the diuretic dose or justify the use of other
drugs as well as the transient early use of renal replace-
ment therapies.
In recent years, authors have found the presence of
renal tubular injury to be the mechanism underlying the
development of AKI, as determined based on the levels
of urinary biomarkers, such as neutrophil gelatinase-
associated lipocalin (NGAL), liver fatty acid-binding pro-
tein (LFABP) and N acetyl-β-D glucosaminidase (NAG),
in patients with contrast media-induced nephropathy or
a history of cardiac surgery and those receiving intensive
care [6–11]. In several studies, including some meta-
analyses, the measurement of NGAL was found to be
particularly useful for detecting AKI in non-surgical
intensive care patients [12–14]. However, cardiac dys-
function induces renal impairment and organ disorders,
and thus these pathologies are comorbidities among non-
surgical intensive care patients. It is therefore reasonable
to detect the presence of AKI using cardiac biomarkers.
The release of heart-type fatty acid-binding protein
(HFABP) following myocardial injury peaks after 4 to
6 h, after which the levels return to baseline within 20 h.
Therefore, myocardial injury can be detected relatively
early using the HFABP level. We hypothesized that the
serum HFABP level is an effective cardiac biomarker for
quickly identifying the presence of AKI on admission and
investigated the diagnostic value of the serum HFABP
level obtained on admission for detecting AKI, particularly
a Class I/F status, according to the etiology of the disease
among non-surgical intensive care patients.
The aim of present study is to elucidate the role of
serum HFABP for quickly identifying the presence of
AKI, especially severe criteria of AKI, on admission in
non-surgical intensive care patients.
Methods
Subjects
We screened 1183 patients who underwent measurement
of three biomarkers (HFABP, N-terminal pro-brain-type
natriuretic peptide [Nt-proBNP], and high-sensitivity
troponin-T [hs-TropT]) in the emergency department at
Chiba Hokusoh Hospital, Nippon Medical School, Japan,
between March 2011 and November 2013. We excluded
patients who were admitted to the general ward, had
received renal replacement therapy prior to admission, or
were diagnosed with acute coronary syndrome (ACS) (e.g.
acute myocardial infarction [AMI] and unstable angina).
As a result, 494 patients admitted to the ICU were
enrolled in this study. (Fig. 1). Patients with the following
diseases were included in the present study: AHF, acute
aortic dissection, pulmonary embolism, arrhythmia, Takot-
subo cardiomyopathy, coronary spasm angina, infectious
disease (sepsis, infective endocarditis, pneumonia, pericar-
ditis, or myocarditis), and emergent respiratory disease.
Serum biomarker measurement
The blood samples were collected in tubes within 10 min
of admission and centrifuged within 30 min after ad-
mission. The serum levels of hs-TropT, Nt-proBNP, and
HFABP were measured additionally using standard labora-
tory parameters via standard enzymatic methods: an elec-
trochemiluminescence immunoassay (Roche Diagnostics
Ltd, Rotkreuz, Switzerland), a chemiluminescent immuno-
assay (CLEIA), and a MARKIT-M HFABP enzyme-linked
immunosorbent assay kit or LIBLIA H-FABP latex agglu-
tination turbidimetric immunoassay (DS Pharma Biomed-
ical, Osaka, Japan). The measurements of these biomarkers
were obtained in all 1183 patients. The lower limit of
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detection for the serum concentration of HFABP was
1.0 ng/mL, while that of hs-TropT was 3 ng/L.
Evaluation of AKI
We evaluated the presence of AKI on admission, using
only the creatinine criteria of the RIFLE classification
[2]. The RIFLE classification is based on the ratio of the
serum creatinine value recorded on admission to the
baseline creatinine value. The patients were classified as
having either no AKI or Class R (risk), Class I (injury),
or Class F (failure) AKI.
The serum creatinine levels in the patients without
chronic kidney disease (CKD) (diagnosed based on their
medical data) were calculated using the Modification of
Diet in Renal Disease (MDRD) equation, as recommended
by the Acute Dialysis Quality Initiative, by solving the
MDRD equation for serum creatinine (CrMDRD), assum-
ing a glomerular filtration rate (GFR) of 75 mL/min/
1.73 m2 [15, 16]. The baseline level of creatinine was the
lowest value recorded during admission in patients with
CKD. The lowest of the creatinine values observed during
hospitalization or the CrMDRD creatinine level served as
the baseline value in patients without CKD.
CKD was diagnosed based on the creatinine value ob-
served within one year. Among patients in whom the cre-
atinine value was not measured within one year before
admission, those who had been previously diagnosed with
CKD in the past were considered to have CKD. CKD was
defined as a low GFR (<60 mL/min/1.73 m2) for more
than 3 months [17]. Patients who did not have any med-
ical records at Chiba Hokusoh Hospital for the three
months prior to admission were diagnosed with CKD
using the data obtained at other institutions for the three-
month period before admission. Kidney damage, as identi-
fied based on abnormal findings on urine and imaging
tests [17], was diagnosed in some patients in the present
study; therefore, CKD was diagnosed only according to a
low GFR with a history exceeding three months. In the
present study, 211 of 494 patients (42.7 %) were diagnosed
with CKD, including 144 patients (68.2 %) in whom the
creatinine value had been measured within the past year
and 67 patients (31.8 %) with a medical history of CKD.
Procedures and prognoses
The occurrence of AKI was evaluated according to the
RIFLE classification on admission. No AKI was present
in 349 patients (no-AKI), while AKI was detected on
admission in 145 patients; the number of patients ac-
cording to class was as follows: Class R (n = 83), Class
I (n = 26), and Class F (n = 36). The serum cardiac bio-
marker levels were compared between four groups
(no-AKI, Class R, Class I, and Class F). The non-
surgical intensive care patients were also assigned to
four groups according to the quartile of the serum
HFABP level: Q1 (n = 124), Q2 (n = 123), Q3 (n = 124)
and Q4 (n = 123). The independent factors for detect-
ing AKI and a Class F status were selected in a univar-
iate analysis for inclusion in the multivariate logistic
regression model.
Receiver-operating characteristic (ROC) curves for the
serum biomarkers were calculated to predict the optimal
cut-off values, and the sensitivity, specificity, and area
under the ROC curve (AUC) were determined in order
to identify the optimal values for predicting AKI and
Class F patients among the overall patients. The cut-off
values were decided by the Youden Method.
The mid-term prognosis, as all-cause death within
180 days, was also evaluated. The patients were clinically
followed up at a routine outpatient clinic. The prognoses
for patients who were followed up at other institutes
were determined via telephone interview. The patients
were assigned to other groups based on the cut-off
values of the ROC curves for the HFABP level and pres-
ence of AKI. The prognostic value of the serum HFABP
1183 patients who underwent the measurement of three biomarkers (HFABP, Nt-proBNP
and hs-TropT) in emergency department.
195 patients admitted to 
general ward.  
988 patients who were admitted in intensive care unit. 
30 Patients who had received renal 
replacement therapy prior to admission. 
958 patients who were admitted in intensive care unit and no renal replacement therapy. 
464 patients who were diagnosed 
as acute coronary syndrome.
494 patients were enrolled. 
Fig. 1 The patient selection process. HFABP, heart-type fatty acid-binding protein; Nt-proBNP, N-terminal pro-brain-type natriuretic peptide;
hs-TropT, high-sensitivity troponin-T
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level and presence of AKI compared with that observed in
the low HFABP and no-AKI group as the referent was
assessed using a Cox regression hazard model. A Cox
regression analysis was performed to obtain the hazard ra-
tio (HR) for 180-day mortality, and the survival rates were
analyzed using Kaplan-Meier curves for each biomarker.
Statistical analysis
All of the data were statistically analyzed using the SPSS
22.0 J software program (SPSS Japan Institute, Tokyo,
Japan). All of the numerical data are expressed as the
mean ± standard deviation or median (range or 25–75 %
interquartile range) by the normality, which was assessed
using the Shapiro-Wilk W test. The unpaired Student’s
t-test or the Mann-Whitney U-test were used to com-
pare two groups, and a one-way analysis of variance or
the Kruskal-Wallis test were used to compare three or
four groups. The comparisons of all proportions were
made using a chi-square analysis for two groups and
Pearson’s bivariate test for three or four groups.
The significant biomarkers indicating AKI and a Class
I/F status on admission were determined using a multi-
variate logistic regression model. ROC curves were cal-
culated to predict the cut-off values, and the sensitivity,
specificity, and area under the curve (AUC) were deter-
mined. The cut-off values were determined using the
Youden Method. A P-value of < 0.05 was considered to
be statistically significant.
The prognostic value of the serum HFABP level in the
low HFABP and AKI group, high HFABP and no-AKI
group, and high HFABP and AKI group compared with
that observed in the low HFABP and no-AKI group as
the referent was assessed using a Cox regression hazard
model. A Cox regression analysis was performed to
obtain the HR for 180-day mortality. Thereafter, a multi-
variate analysis was performed using the variables with a
P-value of <0.05 in the univariate analysis to examine
their independent associations with the 180-day mortal-
ity. The survival rates were analyzed between the groups
assigned based on the cut-off value of the ROC curve
for the HFABP level and classified as having or not
having AKI according to a Kaplan-Meier curve, and




The differences in the patients’ characteristics according
to the RIFLE criteria are shown in Table 1. The patient
cohort was 68.0 % male subjects, with a median age of
71 years. The number of arrhythmia and infectious
disease patients, lactate levels, serum BUN levels, and
serum CRP levels were significantly higher and the
systolic blood pressure (BP) values, pH levels, and serum
hemoglobin levels significantly lower in the AKI group
than in the no-AKI group. In addition, the hs-TropT
levels and Nt-proBNP levels were also significantly
higher in the AKI group than in the no-AKI group.
HFABP and AKI
The distribution of the HFABP levels in the overall
non-surgical intensive care patients is described in
Fig. 2. Among all 494 patients admitted to receive
non-surgical intensive care, the HFABP levels were
<10 ng/mL in 220 patients (44.5 %) and >100 ng/ml
in 37 patients (7.5 %). The median (range) HFABP
levels were significantly higher in the Class F (79.2
[29.9 to 200.3] ng/mL) than in the Class I (41.5 [16.7
to 71.6] ng/mL), the Class R (21.1 [10.2 to 47.9] ng/
mL), and the no-AKI (8.8 [5.4 to 17.7] ng/mL)
groups. (Table 1).
The incidence of AKI and in-hospital mortality by
quartile of HFABP level is noted in Table 2. The rate
of patients classified into the no-AKI, Class R, Class
I, and Class F groups was significantly different
among the quartile groups. The in-hospital mortality
was poorer in the Q4 group than in the Q3, Q2, and
Q1 groups and in the Q3 group than in the Q2 and
Q1 groups.
The results of the multivariate logistic regression
analysis for detecting the presence of AKI showed the
specific biomarkers to be Q2 (odds ratio [OR]: 3.743;
95 % confidence interval [CI]: 1.693–8.274, p = 0.001),
Q3 (OR: 9.427; 95 % CI: 4.124–21.548, p < 0.001) and
Q4 (OR: 28.000; 95 % CI: 11.245–69.720, p < 0.001),
while the markers indicating a Class I/F status were
Q3 (OR: 5.155; 95 % CI: 1.030–25.790, p = 0.047) and
Q4 (OR: 22.978; 95 % CI: 4.814–109.668, p < 0.001)
(Table 3).
Diagnostic value of the H-FABP level
The ROC curves are shown in Fig. 3. The s-HFABP level
demonstrating an optimal balance between sensitivity
and specificity for detecting the presence of AKI (70.3
and 72.8 %, respectively; AUC: 0.774; 95 % CI: 0.728–
0.819) was 15.7 ng/mL for the overall patients, while
that for the Nt-proBNP level was 13,829 ng/L (29.0 and
88.8 %, respectively; AUC: 0.618; 95 % CI: 0.562–0.673),
and that for the hs-TropT level 48 ng/L was (64.8 and
56.3 %; AUC: 0.622; 95 % CI: 0.570–0.675) (Fig. 3-a).
With respect to indicating a Class I/F status, the optimum
levels for sensitivity and specificity were 29.2 ng/mL for
the HFABP level (71.0 and 83.1 %, respectively; AUC:
0.818; 95 % CI: 0.763–0.873), 6583 ng/L for the Nt-
proBNP level (59.7 and 73.4 %, respectively; AUC: 0.691;
95 % CI: 0.616–0.766), and 48 ng/L for the hs-TropT level
(77.4 and 54.1 %, respectively; AUC: 0.666; 95 % CI:
0.604–0.728) (Fig. 3-b).
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Table 1 Patient characteristics and RIFLE criteria
total (n = 494) no AKI (n = 349) AKI
Class R (n = 83) Class I (n = 36) Class F (n = 26) P value
Age (years old) 71 (62–79) 71 (62–80) 71 (64–79) 67 (62–76) 78 (69–81) 0.092
Gender (male, %) 336 (68.0 %) 237 (67.9 %) 56 (67.5 %) 28 (77.8 %) 15 (57.7 %)
Etiology
Acute Heart Failure (yes) 242 (49.0 %) 186 (53.3 %) 37 (44.6 %) 12 (33.3 %) 7 (26.9 %) 0.008
Acute Aortic Dissection (yes) 48 (9.7 %) 34 (9.7 %) 11 (13.3 %) 3 (8.3 %) 0 (0.0 %) 0.255
Pulmonary Thromboembolism (yes) 21 (4.3 %) 17 (4.9 %) 3 (3.6 %) 1 (2.8 %) 0 (0.0 %) 0.624
Arrhythmia (yes) 65 (13.2 %) 38 (10.9 %) 14 (16.9 %) 7 (19.4 %) 6 (23.1 %) 0.109
Coronary Spasms (yes) 22 (4.5 %) 21 (6.0 %) 1 (1.2 %) 0 (0.0 %) 0 (0.0 %) 0.073
Takotsubo Cardiomyopathy (yes) 13 (2.6 %) 10 (2.9 %) 1 (1.2 %) 1 (2.8 %) 1 (3.4 %) 0.829
Infectious disease (yes) 32 (6.5 %) 9 (2.6 %) 9 (10.8 %) 7 (19.4 %) 7 (26.9 %) <0.001
Other Intensive Care disease (yes) 36 (7.3 %) 20 (5.7 %) 6 (7.2 %) 5 (13.9 %) 5 (19.2 %) 0.028
Past medical history
Chronic Kidney Disease (yes) 211 (42.7 %) 159 (45.6 %) 31 (37.3 %) 12 (33.3 %) 9 (34.6 %) 0.249
Hypertension (yes) 360 (72.9 %) 260 (74.5 %) 55 (66.3 %) 25 (69.4 %) 20 (76.9 %) 0.435
Diabetes mellitus (yes) 174 (35.2 %) 115 (33.0 %) 36 (43.4 %) 9 (25.0 %) 14 (53.8 %) 0.032
Dyslipidemia (yes) 234 (47.4 %) 170 (48.7 %) 40 (48.2 %) 14 (38.9 %) 10 (38.5 %) 0.544
Vital signs and status
Systolic blood pressure (mmHg) 147 (116–174) 156 (129–182) 137 (101–164) 115 (103–133) 107 (87–128) <0.001
Diastolic blood pressure (mmHg) 80 (64–100) 84 (70–101) 74 (60–91) 64 (52–74) 55 (44–70) <0.001
Pulse Rate (beats/min) 98 (75–119) 100 (78–120) 92 (67–115) 97 (66–110) 83 (59–120) 0.141
Respiratory Rate (beats/min) 25 (20–32) 25 (20–32) 24 (17–34) 21 (18–27) 20 (15–26) 0.050
Body Temperature (°C) 36.3 (35.7–36.8) 36.3 (35.8–36.7) 36.3 (35.5–36.8) 36.7 (36.2–37.3) 36.6 (35.9–37.5) 0.006
Body Mass Index (%) 22.9 (20.3–25.4) 23.1 (20.4–25.8) 23.0 (21.0–25.2) 21.7 (19.8–23.8) 22.7 (19.0–25.1) 0.094
LVEF (%) 50 (32–65) 50 (35–64) 47 (29–65) 45 (29–69) 50 (45–65) 0.466
Arterial blood gas
pH 7.40 (7.28–7.44) 7.40 (7.29–7.44) 7.37 (7.20–7.42) 7.40 (7.31–7.46) 7.35 (7.27–7.42) 0.052
PCO2 (mmHg) 38 (33–48) 39 (34–48) 36 (33–53) 32 (27–40) 34 (30–43) <0.001
PO2 (mmHg) 101 (73–156) 100 (72–149) 112 (73–181) 116 (80–162) 81 (68–128) 0.249
HCO3 - (mmol/l) 22.4 (19.2–24.9) 23.1 (20.6–25.1) 20.4 (17.8–24.3) 20.2 (15.5–23.5) 18.8 (14.7–23.0) <0.001
SaO2 (%) 97 (94–99) 97 (94–99) 97 (94–99) 98 (96–99) 96 (93–98) 0.243













Hemoglobin (g/dl) 12.6 (10.7–14.3) 12.7 (11.1–14.4) 13.4 (10.8–14.7) 11.3 (9.4–12.7) 9.7 (8.5–11.9) <0.001
BUN (mg/dl) 22.4 (16.5–33.3) 19.9 (15.9–28.2) 24.9 (18.3–33.2) 39.3 (23.8–51.1) 55.6 (46.5–83.1) <0.001
Creatinine (mg/dl) 1.10 (0.82–1.69) 0.99 (0.75–1.35) 1.23 (1.00–1.53) 1.74 (1.12–2.16) 3.27 (2.20–4.84) <0.001
Sodium (mmol/l) 140 (137–142) 140 (138–142) 139 (136–142) 137 (133–142) 139 (136–142) 0.007
Potassium (mmol/l) 4.1 (3.8-4.7) 4.0 (3.7-4.5) 4.3 (3.9-4.9) 4.5 (3.8-5.5) 4.9 (3.9-6.5) <0.001
BS (mg/dl) 157 (122–235) 154 (119–233) 174 (144–303) 143 (124–242) 130 (97–174) <0.001
CRP (mg/dl) 0.61 (0.11–3.17) 0.41 (0.09–1.27) 0.99 (0.14–5.88) 3.34 (0.83–9.08) 3.51 (0.42–8.17) <0.001
Uric Acid (mg/dl) 6.8 (5.2–8.2) 6.4 (5.1–7.6) 8.2 (6.1–9.2) 7.4 (6.7–9.9) 8.4 (6.0–11.8) <0.001
BNP (pg/ml) 431 (95–951) 426 (76–901) 389 (157–750) 691 (139–2007) 437 (263–1231) 0.090
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Prognosis
The multivariate Cox regression model indicated that an
HFABP level of ≥15.7 ng/mL and the presence of AKI
(HR: 11.593, 95 % CI: 5.154–26.078; p < 0.001) were in-
dependent predictors of 180-day mortality (Table 4).
The Kaplan-Meier survival curves showed that the prog-
nosis, including all-cause death, was significantly poorer
in the high serum HFABP with AKI group than in the
high serum HFABP without AKI group, low serum
HFABP with AKI group, and the low serum HFABP
without AKI group (Fig. 4).
Discussion
The serum levels of HFABP were elevated in non-surgical
intensive care patients. An elevated HFABP level may be
useful for detecting the presence of AKI, especially a Class
I/F status.
Serum HFABP levels in ACS patients
We first evaluated all of the patients in the intensive care
unit, including ACS patients, and investigated the efficacy
of the serum HFABP level for detecting AKI. However, the
diagnostic value, as represented by the AUC, was not
adequate among the overall patients. After narrowing down
the study population to the patients in present study,
excluding ACS patients, the diagnostic value increased. In
almost all of the ACS patients, the serum HFABP levels
were elevated due to the presence of immediate and exces-
sive myocardial damage induced by myocardial ischemia.
HFABP is abundant in the cytosol and easily released into
the circulation when the cardiomyocyte membrane is
injured [18]. Therefore, measuring the HFABP level is a
mainstay for early diagnosis of ACS, and this parameter is
used as the gold standard biomarker for detecting ACS in
the early phase [19–22]. The majority of previous reports
about the serum HFABP have focused on ACS patients.
Therefore, ACS, an emergent ischemic heart condition, is
an independent factor for an increased serum HFABP level.
In practice, the serum levels of HFABP were markedly
higher in the ACS patients than in the other etiology
groups in the present study, and some ACS patients with
no-AKI were included in the Q3 and Q4 groups. These
results suggest that patients with ACS should be excluded
when discussing the incidence of AKI.
Serum HFABP levels by disease
The efficacy of the HFABP level except for in ACS
patients was first reported in HF patients. In these
Table 1 Patient characteristics and RIFLE criteria (Continued)
hs-TropT (ng/ml) 0.05 (0.02–0.12) 0.04 (0.02–0.09) 0.05 (0.02–0.18) 0.07 (0.05–0.38) 0.08 (0.05–0.14) <0.001
Nt-proBNP (pg/ml) 2,550 (633–8,653) 2,333 (378–6,753) 2,746 (924–7,958) 6,975 (1,946–47,228) 10,959 (2,686–23,400) <0.001
H-FABP (ng/ml) 11.7 (6.2–27.8) 8.8 (5.4–17.7) 21.1 (10.2–47.9) 41.5 (16.7–71.6) 79.2 (29.9–200.3) <0.001
Mechanical Support (cases) during the ICU stay
NPPV (yes, %) 209 (42.3 %) 161 (46.1 %) 35 (42.2 %) 10 (27.8 %) 3 (11.5 %) 0.002
ETI (yes, %) 121 (24.5 %) 53 (15.2 %) 36 (43.4 %) 18 (50.0 %) 14 (53.8 %) <0.001
Pacing (yes, %) 37 (7.5 %) 20 (5.7 %) 8 (9.6 %) 6 (16.7 %) 3 (11.5 %) 0.069
IABP (yes, %) 26 (5.3 %) 9 (2.6 %) 10 (12.0 %) 5 (13.9 %) 2 (7.7 %) <0.001
PCPS (yes, %) 17 (3.4 %) 5 (1.4 %) 7 (8.4 %) 3 (8.3 %) 2 (7.7 %) 0.002
CHDF (yes, %) 60 (12.1 %) 15 (4.3 %) 11 (13.3 %) 17 (47.2 %) 17 (65.4 %) <0.001
LVEF left ventricular ejection fraction measured on echocardiography, WBC white blood cell, BUN blood urea nitrogen, BS blood sugar, CRP C-reactive protein, BNP
brain natriuretic peptide, hs-TropT high-sensitivity troponin T, Nt-proBNP N-Terminal pro-brain-type natriuretic peptide, H-FABP heart-type fatty acid binding, ICU
intensive care unit, NPPV noninvasive positive pressure ventilation, ETI endotracheal intubation, IABP intra-aortic balloon pumping, PCPS percutaneous cardiopulmonary
support, CHDF continuous hemodiafiltration


























Fig. 2 The distribution of the HFABP levels. The median
value among all 494 intensive care patients was 11.7 ng/ml.
The HFABP level was <10 ng/mL in 220 patients (44.5 %)
and >100 ng/mL in 37 patients (7.5 %). HFABP, heart-type
fatty acid-binding protein
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Table 2 Relationships between the quartiles of HFABP and the incidence of AKI, levels of cardiac markers and in-hospital mortality
Q1 Q2 Q3 Q4
H-FABP≦6.2 (n = 124) 6.3≦H-FABP≦11.6 (n = 123) 11.7≦H-FABP≦27.8 (n = 124) 27.9≦H-FABP (n = 123) p value
Acute kidney injury
no-AKI (yes, %) 113 (91.1 %) 102 (82.9 %) 90 (72.6 %) 44 (35.8 %) <0.001
Class R (yes, %) 9 (7.3 %) 16 (13.0 %) 23 (18.5 %) 35 (28.5 %) <0.001
Class I (yes, %) 1 (0.8 %) 5 (4.1 %) 6 (4.8 %) 24 (19.5 %) <0.001
Class F (yes, %) 1 (0.8 %) 0 (0.0 %) 5 (4.0 %) 20 (16.3 %) <0.001
Biomarkers
hs-TropT (ng/ml) 0.02 (0.01–0.03) 0.04 (0.02–0.06) 0.06 (0.03–0.10) 0.14 (0.06–0.54) <0.001
Nt-proBNP (pg/ml) 351 (68–1,748) 2,401 (925–5,451) 5,739 (1,991–13,267) 7929 (2,164–23,269) <0.001
In-hospital mortality
dead (yes, %) 3 (2.4 %) 5 (4.1 %) 18 (14.5 %) 38 (30.9 %) <0.001
H-FABP heart-type fatty acid binding, LVEF left ventricular ejection fraction measured on echocardiography; WBC white blood cell; BUN blood urea nitrogen, BS
blood sugar, CRP C-reactive protein, BNP brain natriuretic peptide, hs-TropT high-sensitivity troponin T, Nt-proBNP N-Terminal pro-brain-type natriuretic peptide,
hs-CRP high-sensitivity C-reactive protein, NPPV noninvasive positive pressure ventilation, ETI endotracheal intubation, IABP intra-aortic balloon pumping, PCPS
percutaneous cardiopulmonary support, CHDF continuous hemodiafiltration, ICU intensive care unit
p value between the quartiles of H-FABP determined using a variance analysis and the Kruskal-Wallis test
Table 3 Multivariate analysis of the associations between acute kidney injury and the clinical findings
AKI Class I/F
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis




1.000 1.000 1.000 1.000
Q2 (6.3≦H-
FABP≦11.6)
2.453 1.095– 5.498 0.029 3.743 1.693–8.274 0.001 2.585 0.492–13.584 0.262 3.194 0.582–17.523 0.181
Q3 (11.7≦H-
FABP≦27.8)
5.030 2.311–10.947 <0.001 9.427 4.124–21.548 <0.001 5.938 1.288–27.374 0.022 5.155 1.030–25.790 0.046
Q4 (27.9≦H-
FABP)




1.196 0.786–1.819 0.404 0.652 0.373–1.141 0.134
Age (≧71
years old)
0.921 0.626–1.356 0.677 0.887 0.520–1.512 0.659
MBP
(≧102 mmHg)
0.260 0.171–0.393 <0.001 0.264 0.172–0.442 <0.001 0.140 0.067–0.290 <0.001 0.191 0.087–0.416 <0.001
LVEF (≧51 %) 0.757 0.493–1.163 0.204 0.533 0.486–1.453 0.840
Hemoglobin
(≧12.7 g/dl)
0.681 0.461–1.006 0.053 0.259 0.138–0.483 <0.001 0.430 0.212–0.874 0.020
Hs-TropT
(≧0.048 ng/ml)
2.319 1.555–3.458 <0.001 0.736 0.428–1.265 0.267 4.035 2.160–7.536 <0.001 1.220 0.553–2.691 0.623
Nt-ProBNP
(≧2553 pg/ml)
1.665 1.126–2.462 0.011 0.824 0.497–1.366 0.452 2.325 1.322–4.091 0.003 1.023 0.500–2.094 0.950
HR hazard ratio, CI confidence interval, H-FABP heart-type fatty acid binding, MBPmean blood pressure, LVEF left ventricular ejection fraction measured on
echocardiography, Hs-TropT high-sensitivity troponin T, Nt-proBNP N-Terminal pro-brain-type natriuretic peptide
Shirakabe et al. BMC Cardiovascular Disorders  (2016) 16:174 Page 7 of 12
previous reports, the HFABP level exhibited superior
sensitivity to the troponin T level for detecting ongoing
myocardial damage [23] and was reported to be a sensitive
marker of minor myocardial injury in patients with
congestive HF [24]. Furthermore, the serum HFABP level
indicates the presence of latent and ongoing cardiomyo-
cyte damage; therefore, it is a sensitive marker of minor
myocardial injury in patients with congestive HF [25].
Seino et al. first reported that some patients with acute
aortic dissection and pulmonary embolism also ex-
hibit positive test results for HFABP and that 40 % of
patients with non-cardiovascular conditions have an
elevated HFABP level [25]. The authors speculated the
reason for this finding to be the result of diminished renal
clearance [26] and assumed that minor myocardial da-
mage associated with acute hemodynamic deterioration
leads to an elevated HFABP level. Hazui et al. also dem-
onstrated that patients with acute aortic dissection have
elevated HFABP levels [27]. HFABP is present in skeletal
muscle tissue; therefore, HFABP is released into the blood
from skeletal muscle rather than cardiac muscle, and the
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Fig. 3 a The sensitivity and specificity of the HFABP level for detecting AKI were 70.3 and 77.4 % (AUC: 0.774; 95 % CI: 0.728–0.819), respectively,
with a cut-off value of 15.7 ng/mL. b The sensitivity and specificity of the HFABP level for detecting a Class I/F status were 71.0 and 83.1 % (AUC:
0.818; 95 % CI: 0.763–0.873), respectively, with a cut-off value of 29.2 ng/mL for the overall patients. HFABP, heart-type fatty acid-binding protein;
AKI, acute kidney injury; AUC, area under the receiver-operating characteristic curve
Table 4 Cox regression analysis of the associations between 180-day cumulative mortality and the clinical findings
Univariate analysis Multivariate analysis
180-days mortality HR 95 % CI p value HR 95 % CI p value
H-FABP level and AKI status
H-FABP≦15.6 and no-AKI 1.000 1.000
H-FABP≦15.6 and AKI 4.128 1.432–11.898 0.009 2.676 0.920–7.783 0.071
H-FABP≧15.7 and no-AKI 8.070 3.592–18.131 <0.001 9.268 3.835–22.396 <0.001
H-FABP≧15.7 and AKI 14.037 6.556–30.054 <0.001 11.593 5.154–26.078 <0.001
Adjusting factors
Chronic kiedney disease 0.887 0.560–1.405 0.609
Age (≧69 years old) 1.036 0.659–1.629 0.879
MBP (≧99 mmHg) 0.205 0.114–0.366 <0.001 0.239 0.130–0.441 <0.001
LVEF (≧51 %) 0.652 0.396–1.074 0.093
Hemoglobin (≧13.5 g/dl) 0.567 0.352–0.912 0.019 0.990 0.603–1.624 0.968
Hs-TropT (≧0.064 ng/ml) 2.429 1.478–3.994 <0.001 0.818 0.469 –1.424 0.477
Nt-ProBNP (≧930 pg/ml) 1.598 1.001–2.552 0.050
HR hazard ratio, CI confidence interval, H-FABP heart-type fatty acid binding, MBP mean blood pressure, LVEF left ventricular ejection fraction measured on
echocardiography, Hs-TropT high-sensitivity troponin T, Nt-proBNP N-Terminal pro-brain-type natriuretic peptide
Shirakabe et al. BMC Cardiovascular Disorders  (2016) 16:174 Page 8 of 12
from the aortic wall. The HFABP level has also been
reported to be effective for risk stratification in the setting
of pulmonary embolism [28, 29]. Among patients with
pulmonary embolism, the HFABP levels may be elevated
as a consequence of right ventricular wall stress due to a
highly elevated right ventricular afterload.
However, Jo et al. reported that the serum HFABP con-
centrations are frequently elevated in patients with severe
sepsis and septic shock [30]. Because patients with sepsis or
septic shock tend to exhibit multiple organ failure, includ-
ing AKI, and since HFABP is eliminated via renal clearance,
the concentrations of HFABP may be increased in subjects
with a decreased renal function [31]. In addition, during
severe sepsis and septic shock, the catabolism of glycogen
and lipids increases the levels of free fatty acids, which may
directly lead to an elevated HFABP concentration [32].
Furthermore, septic injury induces metabolic lipid disor-
ders and the release of free radicals, resulting in damage
to the vital organs and increased HFABP levels [32]. Such
sequelae would of course be related to sepsis-induced
myocardial dysfunction.
Mechanisms for detecting AKI by serum HFABP levels
The mechanisms underlying an increased HFABP level
might differ based on the ACS situation in intensive care
patients. As stated above, the release of HFABP is postu-
lated in various hypotheses, and minor myocardial injury
would be major reason for an increased HFABP level.
The leakage of small amounts of macromolecules can be
caused by mechanical stretching mechanisms, such as is-
chemic stress induced by non-cardiogenic shock, which
would lead to the release of HFABP into the blood.
However, minor myocardial injury alone may not ad-
equately explain the elevation of the HFABP levels
observed in non-cardiac patients. A reduction in the
amount of skeletal muscle tissue [32] and increase in the
free acids level by the catabolism of glycogen [32] could
also induce an elevation of the H-FABP level. Further-
more, lipid disorders and the release of free radicals
would also lead to increased HFABP levels [32]. Vital
organ functions are damaged in almost all non-surgical
intensive care patients in various situations, which may
result in an increased HFABP level. Therefore, the
degree of leakage of HFABP may be greater in severe-
condition intensive care patients who have suffered mul-
tiple organ failure and vital organ damage. Given that
AKI is a component of multiple organ failure, serum
HFABP level might be increased in AKI patients due
precisely to the multiple organ failure. Serum HFABP is
also excreted by renal tubular cells; therefore, patients
with an acutely diminished renal function—and thus
AKI—are unable to clear large amounts of HFABP.
These proposed mechanisms support the potential utility
of the serum level of HFABP as an effective biomarker































Fig. 4 The Kaplan-Meier survival curves showed that the prognosis, including all-cause death, was significantly poorer in the high serum HFABP
(≥15.7 ng/mL) with AKI group than in the low serum HFABP (<15.7 ng/mL) with AKI group, high serum HFABP without AKI group, and low serum
HFABP without AKI group. HFABP, heart-type fatty acid-binding protein; AKI, acute kidney injury
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However, using the serum HFABP level to detect
patients with AKI would have several limitations in
comparison with other reno-tubular biomarkers such as
serum NGAL level or NAG level, as the elevation of
these reno-tubular biomarkers in serum clearly indicates
renal damage and has superior diagnostic and prognostic
significance [6–11]. NGAL is a 25-kDa protein normally
secreted by renal tubular cells, leukocytes, and several
other types of epithelial cells in response to ischemic or
toxic injury [33]. In patients with AKI, various stresses
first increase the serum NGAL in the circulation, which
induces the activation of neutrophils. Then, the in-
creased amount of NGAL is filtered from the glomerular
filtrate. Some NGAL molecules are reabsorbed by the
damaged proximal tubules, while others are not. In-
creased urinary NGAL is therefore mainly due to im-
paired renal re-absorption [33], and it takes a relatively
long period of time for the urinary NGAL levels to
return to normal. NAG is a lysosomal enzyme which is
abundantly present in the cells of the proximal kidney
tubule, and it can also be used to detect renal injury
[34]. HFABP was categorized as a cardiovascular marker,
not a reno-tubular biomarker. While the serum level of
HFABP may indeed be an effective biomarker for AKI in
the cardiovascular field, it might not be as useful as the
available reno-tubular biomarkers. The predictive per-
formance and scientific/clinical impact might be im-
proved by the combined measurement of NGAL and
HFABP. Two new metrics, the integrated discrimination
improvement (IDI) and net reclassification improvement
(NRI) were effective for improving the diagnostic value
by quantifying the added value of a biomarker to an
existing test [35, 36]. The measurement of serum NGAL
level has already been reported as a definitive biomarker
of AKI in non-surgical intensive care patients [12–14].
Therefore, the diagnostic value of the serum HFABP
level might be increased by adding the serum NGAL
level to it using the IDI and NRI method. Further study
will be required in order to improve the diagnostic value
of AKI based on the results of present study.
Study limitations
Several limitations associated with the present study
warrant mention. First, we were unable to obtain the
medical records for all patients and were obliged to use
the MDRD equation for serum creatinine (CrMDRD),
assuming a GFR of 75 mL/min/1.73 m2 in order to
determine the baseline values. This might be a major
limitation of this study; Pickering et al. reported that a
measured rather than estimated value should be used for
baseline creatinine values in epidemiologic studies of
AKI [37]. However, given that some patients in the
present study had their creatinine levels measured only a
limited number of times for unclear reasons, we had no
choice but to use the MDRD equation. Of note, a new
equation for estimating the GFR, defined as the CKD
epidemiology collaboration (CKD-EPI) equation, was
recently proposed [38]. This equation is reportedly more
accurate than the MDRD study equation [38, 39]. How-
ever, although we tried to innovate this equation, race-
based modifications were needed. While a modified
CKD-EPI for use in Japanese populations has been re-
ported [40], there is still no definitive equation for Asian
populations. We therefore decided against using the
CKD-EPI equation in this study. Second, some of the
urinary and serum biomarkers, such as the urinary
excretion of NGAL, LFABP, and NAG, could not be
evaluated. These untested biomarkers may more clearly
demonstrate the presence of AKI than the serum level of
HFABP. Third, this study was performed at a single
center and included a small number of subjects. The
etiology was mixed, and the number of patients with
each disease may have been too small to accurately
evaluate the incidence of AKI. Fourth, diagnosing CKD
based on the lowest value recorded in the year before
admission is important; however, this was difficult to
achieve in all patients in the present study. The creatin-
ine level before admission was not measured in several
patients (29.7 %), and the diagnosis of CKD was made
based on previous medical records in 67 of 211 patients
(31.8 %). Finally, the technique for measuring the H-FABP
level was changed in July 2012 by the DS Pharma Biome-
dica. We therefore changed our measurement method
from a MARKIT-M HFABP enzyme-linked immunosorb-
ent assay kit to a LIBLIA H-FABP latex agglutination tur-
bidimetric immunoassay. This use of a different method
was another major limitation in the present study;
however, the results from each method correlated well
(r = 0.994). As such, we feel that the values of HFABP
obtained via these different methods were comparable.
Conclusions
The serum HFABP level is an effective biomarker for
detecting AKI, especially a Class I/F status, on admission
and produces an optimum balance between sensitivity
and specificity for indicating the presence of AKI and a
Class I/F status in non-surgical intensive care patients.
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